BeiGene Files SC 13D/A Amendment for Leap Therapeutics

TL;DR

BeiGene updated its Leap Therapeutics stake filing on 10/31. Ownership details TBD.

AI Summary

BeiGene, Ltd. filed an amendment (Amendment No. 2) to its Schedule 13D on October 31, 2024, regarding its holdings in Leap Therapeutics, Inc. The filing indicates a change in the reporting person's beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. BeiGene, Ltd. is listed as the filer, with its business address in Grand Cayman.

Why It Matters

This filing signals a potential shift in the ownership structure or investment strategy of BeiGene, Ltd. concerning Leap Therapeutics, which could impact Leap's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can indicate shifts in strategy or potential future actions that could affect the company's stock price.

Key Players & Entities

• BeiGene, Ltd. (company) — Reporting Person
• Leap Therapeutics, Inc. (company) — Issuer
• 0001651308-24-000147 (filing_id) — Accession Number
• 20241031 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
• $40 million — ed a private placement of approximately $40 million in April 2024, as reported in the Issue

Filing Documents

• leaptherapeuticsschedule13.htm (SC 13D/A) — 40KB
• 0001651308-24-000147.txt ( ) — 42KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of the Original Schedule 13D is hereby amended and restated as follows

Item 5 of the Original Schedule 13D is hereby amended and restated as follows (a) - (b) BeiGene may be deemed to have the following (i) Sole power to vote of direct the vote 1,215,306 (ii) Shared power to vote or direct the vote -0- (iii) Sole power to dispose or direct the disposition of 1,215,306 (iv) Shared power to dispose or direct the disposition of -0- On March 12, 2020, the Issuer issued to the Reporting Person (i) 4,804,637 shares of Common Stock upon conversion of Series B mandatorily convertible cumulative non-voting perpetual preferred stock and (ii) 4,804,637 shares of Common Stock issuable upon the exercise of a currently-exercisable warrant. On September 24, 2021, the Reporting Person purchased 2,543,800 shares of Common Stock of the Issuer pursuant to an underwritten public offering. The ownership percentage reported are based the Issuer having 38,264,464 shares of Common Stock, $0.001 par value, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on August 9, 2024, which gives effect to a reverse stock split conversion of every 10 shares to 1 share which occurred on June 20, 2023 approved by the Issuer's shareholders during the 2023 Annual Meeting of Stockholders on June 16, 2023 (the "Reverse Stock Split"). All amounts of Common Stock presented herein give effect to the Reverse Stock Split. The Issuer has effected a private placement of approximately $40 million in April 2024, as reported in the Issuer's Current Report on Form 8-K, filed with the SEC on April 11, 2024. The Reporting Person did not purchase or sell any shares of Common Stock in the private placement. This Amendment No. 2 is filed with respect to a decrease in the percent of the class beneficially owned by the Reporting Person resulted solely from an increase in the aggregate number of outstanding shares of Common Stock of the Issuer. (c) Recent Transactions. The Reporting Person has not effected any transactions with respect to the Issue

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BEIGENE, LTD. Date October 31, 2024 By s Chan Lee Name Chan Lee Title Senior Vice President, General Counsel

View Full Filing

View this SC 13D/A filing on SEC EDGAR